uniQure NV
Geschlossen
44.72 1.08
Übersicht
Veränderung der Aktienkurses
24h
Min
44.19
Max
45
Einkommen | -28M -81M |
|---|---|
Verkäufe | 2.3M 5.8M |
EPS | -1.22 |
Gewinnspanne | -1,387.759 |
Angestellte | 221 |
EBITDA | -34M -70M |
Nächstes Ergebnis | 9. Nov. 2026 |
|---|
Marktkapitalisierung | 460M 3.1B |
|---|---|
Vorheriger Eröffnungskurs | 43.64 |
Vorheriger Schlusskurs | 44.72 |
uniQure NV Chart
Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.
Ähnliche Nachrichten
Peer-Vergleich
Kursveränderung
uniQure NV Prognose
Finanzen
Vertriebs- und Verwaltungskosten
Betriebsaufwand
Gewinn vor Steuern
Verkäufe
Umsatzkosten
Bruttogewinn aus dem Verkauf
Zinsaufwand für Schulden
EBITDA
Betriebsergebnis
$
Über uniQure NV
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.